Drug Trial Radar · NCT02318368
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
Last checked: Nov 20, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Nov 2014
Primary completion
Jan 2017
Study completion Jan 2017
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Biodesix, Inc.
- First posted
- Dec 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label.
Conditions
- Non-small Cell Lung Cancer
Interventions
FiclatuzumabDrug
ErlotinibDrug
placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Approximately 24 months
Locations
47 sites in 7 countries. Site status is shown where the registry gives one.
UCSF Fresno
Fresno, California
Torrance Memorial Medical Center
Redondo Beach, California
Boca Raton Regional Hospital Lynn Cancer Institute
Boca Raton, Florida
University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach
Deerfield Beach, Florida
Kaiser Permanente Hawaii
Honolulu, Hawaii
Cancer Center of Acadiana
Lafayette, Louisiana
Mayo Clinic
Rochester, Minnesota
Valley Medical Group
Paramus, New Jersey
Queens Hospital Cancer Center
Jamaica, New York
Aultman Hospital
Canton, Ohio
Gabrail Cancer Center
Canton, Ohio
UPMC Cancer Center Cancer
Pittsburgh, Pennsylvania
Huntsman Cancer Institute
Salt Lake City, Utah
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
North Coast Cancer Institute
Coffs Harbour, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Townsville Hospital
Douglas, Queensland, Australia
Icon Cancer Care
Southport, Queensland, Australia
Princess Alexandra Hospital
Wolloongabba, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Eastern Health
Box Hill, Victoria, Australia
Frankston Hospital
Frankston, Victoria, Australia
Ballarat Oncology and Haematology
Wendouree, Victoria, Australia
Queen Mary Hospital
Pok Fu Lam, Hong Kong
Tuen Mun Hospital
Tuenmen, N.T, Hong Kong
AO G.Rummo
Benevento, Italy
Policlinico S.Orsola Malpighi
Bologna, Italy
Istituti Ospitalieri di Cremona - Oncologia
Cremona, Italy
U.O.C. Oncologia
Lucca, Italy
IRCCS Ospedale S.Raffaele
Milan, Italy
Fondazione Salvatore Maugeri
Pavia, Italy
IRCCS Istituto Clinico Humanitas
Rozzano MI, Italy
Ospedale Treviglio-Caravaggio
Treviglio BG, Italy
John Hopkins Singapore International Medical Center
Central Singapore, Singapore
National Cancer Centre
Singapore, Singapore
Chungbuk National University Hospital
Chungcheongbuk-do, South Korea
Chonnam National University Hwasun Hospital
Jeonnam, South Korea
Severance Hospital, Yonsei Uni
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Korea University Guro Hospital
Guro-gu, Seoul, South Korea
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.